ZLD1039

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406819

CAS#: 1826865-46-6

Description: ZLD1039 is a potent, highly selective, and orally bioavailable small molecule inhibitor of EZH2, which inhibited breast tumor growth and metastasis. ZLD1039 considerably inhibited EZH2 methyltransferase activity with nanomolar potency, decreased global histone-3 lysine-27 (H3K27) methylation, and reactivated silenced tumor suppressors connected to increased survival of patients with breast cancer. Comparable to conditional silencing of EZH2, its inhibition by ZLD1039 decreased cell proliferation, cell cycle arrest, and induced apoptosis. ZLD1039 is a promising treatment for breast cancer.


Price and Availability

Size
Price

Size
Price

Size
Price

ZLD1039 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406819
Name: ZLD1039
CAS#: 1826865-46-6
Chemical Formula: C36H48N6O3
Exact Mass: 612.3788
Molecular Weight: 612.819
Elemental Analysis: C, 70.56; H, 7.90; N, 13.71; O, 7.83


Synonym: ZLD1039; ZLD-1039; ZLD 1039.

IUPAC/Chemical Name: 3-[Ethyl(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,5,6,7,8-hexahydro-1-methyl-3-oxo-4-isoquinolinyl)methyl]-2-methyl-5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-benzamide

SMILES Code: O=C(NCC1=C2CCCCC2=C(C)NC1=O)C3=CC(C4=CC=C(N5CCN(C)CC5)N=C4)=CC(N(CC)C6CCOCC6)=C3C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Song X, Gao T, Wang N, Feng Q, You X, Ye T, Lei Q, Zhu Y, Xiong M, Xia Y, Yang
F, Shi Y, Wei Y, Zhang L, Yu L. Corrigendum: Selective inhibition of EZH2 by
ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast
cancer. Sci Rep. 2016 Apr 29;6:24893. doi: 10.1038/srep24893. PubMed PMID:
27128979; PubMed Central PMCID: PMC4850860.

2: Song X, Gao T, Wang N, Feng Q, You X, Ye T, Lei Q, Zhu Y, Xiong M, Xia Y, Yang
F, Shi Y, Wei Y, Zhang L, Yu L. Selective inhibition of EZH2 by ZLD1039 blocks
H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci
Rep. 2016 Feb 12;6:20864. doi: 10.1038/srep20864. PubMed PMID: 26868841; PubMed
Central PMCID: PMC4751454.